TiumBio Past Earnings Performance
Past criteria checks 0/6
TiumBio's earnings have been declining at an average annual rate of -18.3%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 58.3% per year.
Key information
-18.3%
Earnings growth rate
-17.0%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 58.3% |
| Return on equity | -28.6% |
| Net Margin | -201.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How TiumBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 7,910 | -15,936 | 12,740 | 11,700 |
| 31 Mar 24 | 6,690 | -17,407 | 11,926 | 14,594 |
| 31 Dec 23 | 4,899 | -17,911 | 11,610 | 17,867 |
| 30 Sep 23 | 5,446 | -30,986 | 11,259 | 20,181 |
| 30 Jun 23 | 10,131 | -35,515 | 11,799 | 23,028 |
| 31 Mar 23 | 9,292 | -33,585 | 11,080 | 22,556 |
| 31 Dec 22 | 9,118 | -29,853 | 9,999 | 21,287 |
| 30 Sep 22 | 6,079 | -31,947 | 8,671 | 23,372 |
| 30 Jun 22 | 207 | -34,828 | 6,421 | 23,932 |
| 31 Mar 22 | 83 | -32,216 | 5,929 | 27,432 |
| 31 Dec 21 | 57 | -31,637 | 5,008 | 25,801 |
| 30 Sep 21 | 1,236 | -23,582 | 4,386 | 21,096 |
| 30 Jun 21 | 1,053 | -20,046 | 4,138 | 16,776 |
| 31 Mar 21 | 1,049 | -13,669 | 3,674 | 11,083 |
| 31 Dec 20 | 1,049 | -12,119 | 3,504 | 9,830 |
| 30 Sep 20 | 0 | -11,178 | 3,190 | 8,328 |
| 30 Jun 20 | 113 | -9,685 | 2,755 | 7,546 |
| 31 Mar 20 | 113 | -8,482 | 2,534 | 6,410 |
| 31 Dec 19 | 1,113 | -7,091 | 2,440 | 5,858 |
Quality Earnings: A321550 is currently unprofitable.
Growing Profit Margin: A321550 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A321550 is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.
Accelerating Growth: Unable to compare A321550's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A321550 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A321550 has a negative Return on Equity (-28.64%), as it is currently unprofitable.